On May 27, Baoji Pharma-B rose 5.05% in regular trading, trading at 26.12 HKD/share, with trading volume of approximately 82.26 million HKD. The movement was driven by multiple positive catalysts including a new chairman appointment and pipeline advancement.

On May 26, the company announced that Dr. Liu Yanjun was appointed as Chairman of the second Board of Directors, with a three-year term commencing immediately. Additionally, Wang Zheng and Li Cui were re-elected as executive directors, while several non-executive and independent directors were also re-elected, establishing a complete new governance structure.

On the pipeline front, the company's core product, injectable KJ103 — a globally first-in-class recombinant IgG-degrading enzyme indicated for desensitization treatment in highly sensitized kidney transplant patients — has been proposed for priority review. The stock had previously plunged approximately 65% since late April and remained at depressed levels. The controlling shareholder has expressed intent to increase holdings, and the combination of stabilized management and research progress appears to be restoring market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)